Lilly starts phase 3 test of COVID-19 antibody in nursing homes Genscript chief, the majority shareholder of Legend, becomes China biotech’s new CEO Immunic’s multiple sclerosis med trounces placebo in phase 2 Aslan hires Kobayashi to add IL-13 clinical trial expertise Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO Siemens Healthineers moves deeper into cancer care, picking up radiotherapy developer Varian Medical for $16.4B Featured Story | By Nick Paul Taylor Eli Lilly has started a phase 3 trial to evaluate whether its antibody LY-CoV555 stops the residents of nursing homes from developing COVID-19. Lilly has created customized mobile research units to run the clinical trial at nursing homes as the long-term care facilities lack experience running studies. read more |
| |
|---|
|
Top Stories By Ben Adams After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top. read more By Amirah Al Idrus Chalk one up for Immunic Therapeutics’ lead asset—the drug outshone placebo at reducing damage to myelin, the fatty substance that coats and protects nerve fibers, in patients with the relapsing form of multiple sclerosis. With these topline data in hand, the company will continue gearing up for a phase 3 program. read more By Nick Paul Taylor Aslan Pharmaceuticals has named Kenneth Kobayashi as its chief medical officer. The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival. read more By Ben Adams Preclinical protein degradation biotech Kymera Therapeutics has a great year, nabbing a $102 million round for its march to the clinic, as well as a major tie up with French Big Pharma Sanofi. read more By Conor Hale Siemens Healthineers has moved to take over Varian Medical Systems, makers of radiation therapy hardware and software, to build out its cancer care offerings and provide a platform spanning screening and diagnosis to treatment delivery and recovery. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. |
